Tempus joins as a second commercial laboratory partnership to support oncology-focused access within CellCarta&#39;s CDx Accelerator Model.MONTREAL, Aug. 6, 2026 /PRNewswire/ -- CellCarta, a global CRO laboratory

<p xmlns="http://www.w3.org/1999/xhtml">Tempus joins as a second commercial laboratory partnership to support oncology-focused access within CellCarta&#39;s CDx Accelerator Model.</p><p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">MONTREAL</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">Aug. 6, 2026</span> /PRNewswire/ -- CellCarta, a global CRO laboratory supporting the biopharmaceutical industry, today announced a strategic collaboration with Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/TEM">TEM</a>). Under the agreement, CellCarta will include Tempus in its CDx Commercialization Lab Network as the network&#39;s second commercial laboratory partner, strengthening oncology-focused companion diagnostics offerings to biopharma sponsors.</p>
    <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
                <p xmlns="http://www.w3.org/1999/xhtml">
                    <img xmlns="http://www.w3.org/1999/xhtml" src="https://mmx.prnewswire.com/media/MS1800762/CellCarta-Logo.jpg?id=OA2824599" title="About CellCarta: CellCarta is a leading global CRO laboratory to the biopharmaceutical and biotechnology industries, partnering with translational medicine, biomarker, and clinical development teams to generate reliable, regulator-ready data. With fully owned and harmonized global laboratory operations, CellCarta delivers integrated capabilities spanning immunology, histopathology, proteomics, and genomics, supported by comprehensive sample management and logistics solutions." alt="About CellCarta: CellCarta is a leading global CRO laboratory to the biopharmaceutical and biotechnology industries, partnering with translational medicine, biomarker, and clinical development teams to generate reliable, regulator-ready data. With fully owned and harmonized global laboratory operations, CellCarta delivers integrated capabilities spanning immunology, histopathology, proteomics, and genomics, supported by comprehensive sample management and logistics solutions."></img>
                </p>
    </div>
<p xmlns="http://www.w3.org/1999/xhtml">Within the CellCarta network, the collaboration gives biopharma sponsors a more direct route from companion diagnostic development and regulatory approval to commercial use in U.S. oncology practice. CellCarta develops and validates the CDx, generates the analytical and clinical evidence package, supports regulatory submissions, and performs centralized immunohistochemistry (IHC) and tissue-based testing. For sponsors within the CellCarta CDx Commercialization Lab Network, Tempus will support provider test ordering through Tempus Hub, routing sample testing to CellCarta and transmitting results back to ordering healthcare providers.</p><p xmlns="http://www.w3.org/1999/xhtml">Tempus joins Sonic Healthcare USA as the second member of CellCarta&#39;s CDx Commercialization Lab Network, expanding the network&#39;s specialized oncology capabilities alongside Sonic&#39;s broad clinical and anatomic pathology reach across multiple disease areas. The Lab Network is part of CellCarta&#39;s CDx Accelerator Model, a flexible and modular framework organized around four stages: Build, Validate, Launch, and Transfer. Sponsors can engage CellCarta at the stage that fits their program—from assay development and validation through clinical deployment and regulatory submission. Following approval, CellCarta activates its Commercialization Lab Network partners, such as Tempus and Sonic, to support commercial launch strategies.</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;Tempus materially strengthens the oncology dimension of our commercialization model,&#34; said Ehab A. El-Gabry, MD, Chief Medical Officer and Head of Companion Diagnostics at CellCarta. &#34;Sponsors can develop and validate a companion diagnostic at CellCarta, pursue a single-site approval strategy through our flexible and modular CDx Accelerator Model, and then use an established oncology diagnostics platform to support physician access and ordering. This connects regulatory execution with the realities of commercial launch.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;Biopharma sponsors should not have to choose between the speed and control of a centralized CDx strategy and a credible path to physicians and patients,&#34; said Christopher Ung, Chief Scientific Business Officer of CellCarta. &#34;Adding Tempus to our network creates a powerful route into U.S. oncology practice. It gives sponsors a practical commercialization channel from a company that oncologists already know and use, while CellCarta maintains continuity from development and regulatory approval through testing.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">CellCarta launched its CDx Commercialization Lab Network to address a common gap in companion diagnostic programs: securing regulatory approval does not by itself create the commercial infrastructure required for physicians to order a test and for patients to access it. The network connects CellCarta&#39;s development, regulatory, and testing capabilities with commercial laboratory partners that have established provider relationships and ordering channels.</p><p xmlns="http://www.w3.org/1999/xhtml">CellCarta intends to continue expanding the network by geography, therapeutic area, and commercial capability. The company&#39;s objective is to give sponsors multiple pathways for launching centralized companion diagnostics while retaining flexibility for later expansion through additional laboratories or an IVD kitted solution.</p><p xmlns="http://www.w3.org/1999/xhtml">To learn more about CellCarta&#39;s companion diagnostic capabilities, visit <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4746366-1&amp;h=3938991042&amp;u=https%3A%2F%2Fcellcarta.com%2Fcdx-services%2F&amp;a=https%3A%2F%2Fcellcarta.com%2Fcdx-services%2F" target="_blank" rel="nofollow">https://cellcarta.com/cdx-services/</a> </p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About CellCarta</b></p><p xmlns="http://www.w3.org/1999/xhtml">CellCarta is a global CRO laboratory supporting the biopharmaceutical industry. With CAP accreditations and CLIA certifications for specific testing methods and facilities in Canada, USA, Belgium, Australia, and China, CellCarta provides biomarker testing services and customized solutions to pharmaceutical and biotechnology companies. By integrating analytical platforms in immunology, histopathology, proteomics, and genomics, along with sample management and logistics services, CellCarta supports the drug development cycle from discovery to late-stage clinical trials. Visit cellcarta.com and connect with us on LinkedIn and X.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Media Contacts</b></p><p xmlns="http://www.w3.org/1999/xhtml">Stéphanie Bussières-Marmen, PhD<br xmlns="http://www.w3.org/1999/xhtml"></br>Director, Global Marketing<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:media@cellcarta.com" target="_blank" rel="nofollow">media@cellcarta.com</a></p><p xmlns="http://www.w3.org/1999/xhtml">Melanie Williams<br xmlns="http://www.w3.org/1999/xhtml"></br>Senior Marketing Communications Specialist, Supreme Optimization<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:melanie.williams@supremeopti.com" target="_blank" rel="nofollow">melanie.williams@supremeopti.com</a></p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=LA19865&amp;sd=2026-08-06"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/cellcarta-adds-tempus-to-cdx-commercialization-lab-network-302844793.html" target="_blank">https://www.prnewswire.com/news-releases/cellcarta-adds-tempus-to-cdx-commercialization-lab-network-302844793.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE CellCarta</p>

CellCarta Adds Tempus to CDx Commercialization Lab Network

Tempus Joins CellCarta CDx Network as Second Oncology Lab Partner

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Tempus joins as a second commercial laboratory partnership to support oncology-focused access within CellCarta&amp;#39;s CDx Accelerator Model.MONTREAL, Aug. 6, 2026 /PRNewswire/ -- CellCarta, a global CRO laboratory</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Tempus AI (TEM) joins CellCarta&#039;s CDx Commercialization Lab Network as the second commercial lab partner, expanding oncology companion diagnostics access for biopharma sponsors. The collaboration links development, regulatory submission, and commercial launch through Tempus Hub, routing provider orders to CellCarta and returning results to clinicians. The move signals potential longer-term revenue increases from CDx commercialization but lacks immediate financial figures.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Tempus becomes second commercial lab partner in CellCarta&#039;s CDx Network. Strengthens oncology CDx access.</li><li>Gives sponsors direct CDx development-to-launch route. Tempus will route testing.</li><li>Tempus strengthens oncology focus within CellCarta&#039;s CDx Accelerator Model. Network expansion planned.</li><li>Sonic Healthcare USA remains first network partner. Tempus adds oncology-specific execution.</li><li>No immediate revenue figures disclosed; long-term upside possible.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Tempus AI, Inc. (TEM)</strong>: Becomes second commercial lab partner in CellCarta&#039;s CDx Network; potential near-term strategic revenue upside.</li><li><strong>CellCarta (Private)</strong>: CDx Commercialization Lab Network partner; expands oncology diagnostics access.</li><li><strong>Sonic Healthcare USA (Private)</strong>: First network partner; broad clinical and anatomic pathology reach.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>Industry News: This collaboration expands the ecosystem for oncology CDx deployment, potentially accelerating adoption and revenue opportunities for TEM through a centralized commercialization pathway.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Expansion of CellCarta&#039;s network could unlock longer-term TEM revenue opportunities.</li><li>Tempus Hub integration may boost provider test ordering volume.</li><li>Absence of immediate revenue figures may limit near-term TEM stock reaction.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date: Aug 6, 2026.</li><li>Tempus named second commercial lab partner in CellCarta&#039;s CDx Network.</li><li>CDx Accelerator Model stages: Build, Validate, Launch, Transfer.</li><li>Tempus to route provider test ordering via Tempus Hub.</li><li>Sonic Healthcare USA is the first network partner.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish over 6–12 months for TEM as CDx commercialization expands.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml">Tempus joins as a second commercial laboratory partnership to support oncology-focused access within CellCarta&#39;s CDx Accelerator Model.</p><p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">MONTREAL</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">Aug. 6, 2026</span> /PRNewswire/ -- CellCarta, a global CRO laboratory supporting the biopharmaceutical industry, today announced a strategic collaboration with Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/TEM">TEM</a>). Under the agreement, CellCarta will include Tempus in its CDx Commercialization Lab Network as the network&#39;s second commercial laboratory partner, strengthening oncology-focused companion diagnostics offerings to biopharma sponsors.</p>
    <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
                <p xmlns="http://www.w3.org/1999/xhtml">
                    <img xmlns="http://www.w3.org/1999/xhtml" src="https://mmx.prnewswire.com/media/MS1800762/CellCarta-Logo.jpg?id=OA2824599" title="About CellCarta: CellCarta is a leading global CRO laboratory to the biopharmaceutical and biotechnology industries, partnering with translational medicine, biomarker, and clinical development teams to generate reliable, regulator-ready data. With fully owned and harmonized global laboratory operations, CellCarta delivers integrated capabilities spanning immunology, histopathology, proteomics, and genomics, supported by comprehensive sample management and logistics solutions." alt="About CellCarta: CellCarta is a leading global CRO laboratory to the biopharmaceutical and biotechnology industries, partnering with translational medicine, biomarker, and clinical development teams to generate reliable, regulator-ready data. With fully owned and harmonized global laboratory operations, CellCarta delivers integrated capabilities spanning immunology, histopathology, proteomics, and genomics, supported by comprehensive sample management and logistics solutions."></img>
                </p>
    </div>
<p xmlns="http://www.w3.org/1999/xhtml">Within the CellCarta network, the collaboration gives biopharma sponsors a more direct route from companion diagnostic development and regulatory approval to commercial use in U.S. oncology practice. CellCarta develops and validates the CDx, generates the analytical and clinical evidence package, supports regulatory submissions, and performs centralized immunohistochemistry (IHC) and tissue-based testing. For sponsors within the CellCarta CDx Commercialization Lab Network, Tempus will support provider test ordering through Tempus Hub, routing sample testing to CellCarta and transmitting results back to ordering healthcare providers.</p><p xmlns="http://www.w3.org/1999/xhtml">Tempus joins Sonic Healthcare USA as the second member of CellCarta&#39;s CDx Commercialization Lab Network, expanding the network&#39;s specialized oncology capabilities alongside Sonic&#39;s broad clinical and anatomic pathology reach across multiple disease areas. The Lab Network is part of CellCarta&#39;s CDx Accelerator Model, a flexible and modular framework organized around four stages: Build, Validate, Launch, and Transfer. Sponsors can engage CellCarta at the stage that fits their program—from assay development and validation through clinical deployment and regulatory submission. Following approval, CellCarta activates its Commercialization Lab Network partners, such as Tempus and Sonic, to support commercial launch strategies.</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;Tempus materially strengthens the oncology dimension of our commercialization model,&#34; said Ehab A. El-Gabry, MD, Chief Medical Officer and Head of Companion Diagnostics at CellCarta. &#34;Sponsors can develop and validate a companion diagnostic at CellCarta, pursue a single-site approval strategy through our flexible and modular CDx Accelerator Model, and then use an established oncology diagnostics platform to support physician access and ordering. This connects regulatory execution with the realities of commercial launch.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;Biopharma sponsors should not have to choose between the speed and control of a centralized CDx strategy and a credible path to physicians and patients,&#34; said Christopher Ung, Chief Scientific Business Officer of CellCarta. &#34;Adding Tempus to our network creates a powerful route into U.S. oncology practice. It gives sponsors a practical commercialization channel from a company that oncologists already know and use, while CellCarta maintains continuity from development and regulatory approval through testing.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">CellCarta launched its CDx Commercialization Lab Network to address a common gap in companion diagnostic programs: securing regulatory approval does not by itself create the commercial infrastructure required for physicians to order a test and for patients to access it. The network connects CellCarta&#39;s development, regulatory, and testing capabilities with commercial laboratory partners that have established provider relationships and ordering channels.</p><p xmlns="http://www.w3.org/1999/xhtml">CellCarta intends to continue expanding the network by geography, therapeutic area, and commercial capability. The company&#39;s objective is to give sponsors multiple pathways for launching centralized companion diagnostics while retaining flexibility for later expansion through additional laboratories or an IVD kitted solution.</p><p xmlns="http://www.w3.org/1999/xhtml">To learn more about CellCarta&#39;s companion diagnostic capabilities, visit <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4746366-1&amp;h=3938991042&amp;u=https%3A%2F%2Fcellcarta.com%2Fcdx-services%2F&amp;a=https%3A%2F%2Fcellcarta.com%2Fcdx-services%2F" target="_blank" rel="nofollow">https://cellcarta.com/cdx-services/</a> </p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About CellCarta</b></p><p xmlns="http://www.w3.org/1999/xhtml">CellCarta is a global CRO laboratory supporting the biopharmaceutical industry. With CAP accreditations and CLIA certifications for specific testing methods and facilities in Canada, USA, Belgium, Australia, and China, CellCarta provides biomarker testing services and customized solutions to pharmaceutical and biotechnology companies. By integrating analytical platforms in immunology, histopathology, proteomics, and genomics, along with sample management and logistics services, CellCarta supports the drug development cycle from discovery to late-stage clinical trials. Visit cellcarta.com and connect with us on LinkedIn and X.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Media Contacts</b></p><p xmlns="http://www.w3.org/1999/xhtml">Stéphanie Bussières-Marmen, PhD<br xmlns="http://www.w3.org/1999/xhtml"></br>Director, Global Marketing<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:media@cellcarta.com" target="_blank" rel="nofollow">media@cellcarta.com</a></p><p xmlns="http://www.w3.org/1999/xhtml">Melanie Williams<br xmlns="http://www.w3.org/1999/xhtml"></br>Senior Marketing Communications Specialist, Supreme Optimization<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:melanie.williams@supremeopti.com" target="_blank" rel="nofollow">melanie.williams@supremeopti.com</a></p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=LA19865&amp;sd=2026-08-06"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/cellcarta-adds-tempus-to-cdx-commercialization-lab-network-302844793.html" target="_blank">https://www.prnewswire.com/news-releases/cellcarta-adds-tempus-to-cdx-commercialization-lab-network-302844793.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE CellCarta</p>

Tempus AI (TEM) joins CellCarta's CDx Commercialization Lab Network as the second commercial lab partner, expanding oncology companion diagnostics access for biopharma sponsors. The collaboration links development, regulatory submission, and commercial launch through Tempus Hub, routing provider orders to CellCarta and returning results to clinicians. The move signals potential longer-term revenue increases from CDx commercialization but lacks immediate financial figures.

News insight

CellCarta Adds Tempus to CDx Commercialization Lab Network

AI summary

Sentiment rationale

Key facts

Industry News